Achilles Therapeutics Announces Pricing of Initial Public Offering
March 30 2021 - 7:00PM
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage
biopharmaceutical company developing precision T cell therapies to
treat solid tumors, today announced the pricing of its initial
public offering in the United States of 9,750,000 American
Depositary Shares (“ADSs”) representing 9,750,000 ordinary shares
at an initial public offering price of $18.00 per ADS for total
gross proceeds of $175.5 million. All ADSs sold in the offering are
being offered by Achilles. The ADSs are expected to begin trading
on The Nasdaq Global Select Market on March 31, 2021 under the
ticker symbol “ACHL.” In addition, Achilles has granted the
underwriters a 30-day option to purchase up to an additional
1,462,500 ADSs at the initial public offering price, less
underwriting discounts and commissions. The offering is expected to
close on April 6, 2021, subject to customary closing conditions.
J.P. Morgan, BofA Securities and Piper Sandler
are acting as joint book-running managers for the offering.
Chardan, Oppenheimer & Co, and Kempen & Co are acting as
co-managers.
A registration statement relating to these
securities was declared effective on March 30, 2021. The securities
referred to in this announcement are to be offered only by means of
a prospectus. A copy of the final prospectus, when available, may
be obtained from:
- J.P. Morgan Securities LLC, Attention Equity Syndicate Desk,
383 Madison Avenue, New York, New York 10179, or via email:
prospectuseq_fi@jpmchase.com;
- BofA Securities, Attention: Prospectus Department,
NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC
28255-0001, or via email: dg.prospectus_requests@bofa.com; or
- Piper Sandler & Co., Attention:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN
55402, by telephone: (800) 747-3924, or via email:
prospectus@psc.com.
About Achilles Therapeutics
Achilles is a clinical-stage, biopharmaceutical
company developing precision T cell therapies targeting clonal
neoantigens: protein markers unique to the individual that are
expressed on the surface of every cancer cell. Achilles has two
ongoing Phase I/IIa trials, the CHIRON trial in patients with
advanced non-small cell lung cancer (NSCLC) and the THETIS trial in
patients with recurrent or metastatic melanoma. Achilles uses DNA
sequencing data from each patient, together with its proprietary
PELEUS™ bioinformatics platform, to identify clonal neoantigens
specific to that patient, and then develop precision T cell-based
product candidates specifically targeting those clonal
neoantigens.
Lee M. Stern – VP, IR & External
Communications+1 (332) 373-2634l.stern@achillestx.com
Consilium Strategic CommunicationsMary-Jane
Elliott, Sukaina Virji, Melissa Gardiner+44 (0) 203 709
5000achillestx@consilium-comms.com
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Jul 2023 to Jul 2024